Bank of Montreal’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $155K | Buy |
17,667
+753
| +4% | +$5.7K | ﹤0.01% | 3105 |
|
|
2026
Q1 | $130K | Buy |
16,914
+6,893
| +69% | +$47.2K | ﹤0.01% | 3064 |
|
|
2025
Q4 | $19.8K | Sell |
10,021
-2,501
| -20% | -$5.67K | ﹤0.01% | 3351 |
|
|
2025
Q3 | $30.8K | Hold |
12,522
| – | – | ﹤0.01% | 3211 |
|
|
2025
Q2 | $33.1K | Sell |
12,522
-1,702
| -12% | -$4.58K | ﹤0.01% | 3217 |
|
|
2025
Q1 | $42.8K | Buy |
14,224
+1,502
| +12% | +$4.55K | ﹤0.01% | 3096 |
|
|
2024
Q4 | $32.6K | Sell |
12,722
-249,200
| -95% | -$1.04M | ﹤0.01% | 3190 |
|
|
2024
Q3 | $1.03M | Buy |
261,922
+250,900
| +2,276% | +$1.16M | ﹤0.01% | 2023 |
|
|
2024
Q2 | $80.2K | Sell |
11,022
-14,400
| -57% | -$94.9K | ﹤0.01% | 3304 |
|
|
2024
Q1 | $140K | Sell |
25,422
-36,999
| -59% | -$168K | ﹤0.01% | 3195 |
|
|
2023
Q4 | $325K | Buy |
62,421
+14,061
| +29% | +$44.1K | ﹤0.01% | 2809 |
|
|
2023
Q3 | $87K | Buy |
+48,360
| New | +$97.1K | ﹤0.01% | 3315 |
|
|
2023
Q2 | – | Sell |
-101,469
| Closed | -$196K | – | 4123 |
|
|
2023
Q1 | $196K | Buy |
101,469
+3,508
| +4% | +$10.9K | ﹤0.01% | 3023 |
|
|
2022
Q4 | $503K | Buy |
97,961
+201
| +0.2% | +$1.1K | ﹤0.01% | 2606 |
|
|
2022
Q3 | $517K | Buy |
+97,760
| New | +$445K | ﹤0.01% | 2562 |
|
|
2021
Q2 | – | Sell |
-32,648
| Closed | -$610K | – | 4234 |
|
|
2021
Q1 | $610K | Buy |
32,648
+24,494
| +300% | +$635K | ﹤0.01% | 2522 |
|
|
2020
Q4 | $117K | Buy |
8,154
+3,392
| +71% | +$32.6K | ﹤0.01% | 3499 |
|
|
2020
Q3 | $36K | Buy |
4,762
+2,473
| +108% | +$24.7K | ﹤0.01% | 3566 |
|
|
2020
Q2 | $32K | Buy |
+2,289
| New | +$12.9K | ﹤0.01% | 3633 |
|
|
2020
Q1 | – | Sell |
-30,300
| Closed | -$115K | – | 4352 |
|
|
2019
Q4 | $115K | Hold |
30,300
| – | – | ﹤0.01% | 3426 |
|
|
2019
Q3 | $37K | Buy |
+30,300
| New | +$37.6K | ﹤0.01% | 3770 |
|
|
2019
Q1 | – | Sell |
-379
| Closed | – | – | 4510 |
|
|
2018
Q4 | $0 | Sell |
379
-4
| -1% | -$9 | ﹤0.01% | 4742 |
|
|
2018
Q3 | $2K | Sell |
383
-2
| -0.5% | -$6 | ﹤0.01% | 4358 |
|
|
2018
Q2 | $2K | Buy |
+385
| New | +$1.43K | ﹤0.01% | 4358 |
|
|
2017
Q4 | – | Sell |
-3,500
| Closed | -$19K | – | 4232 |
|
|
2017
Q3 | $19K | Sell |
3,500
-26,291
| -88% | -$162K | ﹤0.01% | 3536 |
|
|
2017
Q2 | $226K | Buy |
+29,791
| New | +$129K | ﹤0.01% | 2607 |
|
Other funds holding IBRX
Bank of Montreal's IBRX Position: Q2 2026 in Review
Bank of Montreal increased its ImmunityBio (IBRX) stake by 4.5% in Q2 2026, buying an estimated $5.7K and bringing the position to 17,667 shares worth $155K. The position accounts for ﹤0.01% of the portfolio, ranked #3105.
Bank of Montreal first reported a position in IBRX in Q2 2017 and has held it in 26 quarters since. The position peaked at $1.03M in Q3 2024. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.
- Bank of Montreal held 17,667 shares of ImmunityBio worth $155K as of Q2 2026.
- Bank of Montreal bought 753 ImmunityBio shares in Q2 2026, an estimated $5.7K.
- ImmunityBio made up ﹤0.01% of Bank of Montreal's portfolio in Q2 2026, its #3105 holding.
- Bank of Montreal first reported a position in ImmunityBio in Q2 2017 and has held it in 26 quarters since.
- Bank of Montreal's ImmunityBio position peaked at $1.03M in Q3 2024.
- 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.
Based on Bank of Montreal's 13F filing for Q2 2026, filed 12 Aug 2026.